Medication Therapy Management: Focus on Diabetes, Insulin, and Incretin Therapies

Medication Therapy Management: Focus on Diabetes, Insulin, and Incretin Therapies

Please read through the following information and click continue.

ACPE Universal Program Number: 207-000-08-100-H01-P and 207-000-08-100-H01-T
Release Date: October 12, 2008
Expiration Date: October 12, 2011

Statement of Need
Diabetes is a disease state that often requires multiple medications and has many treatment regimens. This variety of therapy options as well as the co-morbidities associated with diabetes such as CVD, HTN, and diabetic peripheral neuropathy often means that patients are on multiple medications from multiple practitioners. Because of this, the value of pharmacists as the drug experts for these patients is particularly important. In addition the pharmacist is often the only health care provider to have a complete list of medications for the patient.

Pharmacists can make a difference in patient care by helping patients with polypharmacy issues and advising them and their prescribers of medication interactions and possible side effects that can contribute to hypo- or hyperglycemia. Medication therapy management (MTM) is a growing trend for practitioners in community pharmacies, and diabetes is a prime candidate for delivery of MTM services. This continuing education program will enhance pharmacists’ knowledge of the essential elements of MTM and diabetes, and the specific roles of insulin analogs and incretin therapies for managing hyperglycemia. MTM roleplaying will illustrate how effective pharmacists’ counseling can be with regard to insulin analog and GLP-1 analog therapy.

Learning Objectives
Upon successful completion of this activity, the pharmacist should be able to:

  1. State the 5 core elements of medication therapy management services and summarize changes included in the 2008 updated to MTM criteria.
  2. Provide counseling tips to encourage better adherence to diabetes therapy to improve diabetes outcomes.
  3. State glycemic goals (A1C, FPG, and PPG goals) and describe to patients the need for both adherence to diabetes therapy and changes to therapy over the course of time.
  4. Identify patients in your practice who would benefit from intensification of diabetes therapy.
  5. Outline the key elements to be covered in a medication therapy management encountered with a patient on multiple drugs who presents with a new prescription for insulin analog or incretin mimetic.

Target Audience
The target audience for this activity is pharmacists and pharmacy technicians.

Instructions for Participation
To receive a certificate of completion that indicates your eligibility for continuing education credit, you must:

  • Review the content of the activity.
  • Successfully complete the post-test (70% or higher).
  • You will have two (2) opportunities to successfully complete the activity.

Your statement of credit will be issued immediately upon successful completion of the post-test and submission of the evaluation.

There is no fee for this activity.

ACPE logoNCPA is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program will provide 1.5 contact hours (.15 CEUs) of continuing pharmacy education credit under the number 207-000-08-100-H01-P and 207-000-08-100-H01-T.

David L. Joffe, BSPharm, CDE, FACA (click here to view bio)
Program Chairman
University of Florida College of Pharmacy
St Petersburg, Florida

Pam Marquess, PharmD (click here to view bio)
East Marietta Drug Company
Marietta, Georgia

Jerry Meece, RPh, FACA, CDM, CDE (click here to view bio)
Director of Clinical Services
Plaza Pharmacy and Wellness Center
Gainesville, Texas

Teresa L. Pearson, MS, RN, CDE (click here to view bio)
Diabetes Care
Fairview Health Services
Edina, Minnesota

Disclosure Declaration
It is the policy of the National Community Pharmacists Association (NCPA) to ensure independence, balance, objectivity, scientific rigor, and integrity in all of their continuing education activities.

The author, sponsor, and publisher of this continuing education activity have made all reasonable efforts to ensure that information contained herein is accurate in accordance with the latest available scientific knowledge at the time of accreditation of this continuing education program. Information regarding drugs (e.g., their administration, dosages, contraindications, adverse reactions, interactions, special warnings, precautions) and drug delivery systems are subject to change, however, and the reader is advised to check the manufacturer's package insert for information concerning recommended dosage and potential problems or cautions prior to dispensing or administering the drug or using the drug delivery systems.

Approval of credit for this continuing education activity does not imply endorsement by NCPA of any product or manufacturer identified.

Any medications or treatment methods suggested in this CE activity should not be used by the practitioner without evaluation of their patient's condition(s) and possible contraindication(s) or danger(s) of use of any specific medication.

Commercial Support Statement
Commercial support provided by Novo Nordisk.
Novo Nordisk logo

Software Requirements

Internet Explorer 5.5 or greater
Windows 2000 or greater
Sound Card & Speakers
800 x 600 Minimum Monitor Resolution
(1024 x 768 Recommended)
Flash Player Plug-in (9.0 or later)
   Check your version here.

*Adobe Acrobat Reader

*Required to view Printable PDF Version

Internet Explorer is not supported on the Mac
Mac OS 10.2.8
Sound Card & Speakers
800 x 600 Minimum Monitor Resolution
(1024 x 768 Recommended)
Flash Player Plug-in (9.0 or later)
   Check your version here.
*Adobe Acrobat Reader